semaj83/ctmatch_classification huggingface dataset:
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cytomegalovirus Infections Allogeneic stem cell transplant recipient Recipient or donor CMV seropositive Have transplant engraftment Able to swallow tablets  CMV organ disease HIV infection Use of other anti-CMV therapy post-transplant
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Influenza No contraindications to vaccination as specified in the "Green Book" Immunisation Against Infectious Disease, HMSO Written informed consent obtained Subject aged no less than 50 years 0 days and no older than 79 years and 364 days at enrollment
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 10.0-75.0,  Mycobacterium Infections, Atypical Granulomatous Disease, Chronic Job's Syndrome Influenza, Human FOR to 75 years of age Enrolled without regard to gender, race, or ethnicity NIH employees or non-employees eligible Able to provide proof of identity Able and willing to complete the informed consent process Able and willing to arrange to have another person drive them home after the procedure Able and willing not to eat or drink anything for 6 hours prior and 2 hours after the procedure Willing to donate blood and respiratory tract samples for storage to be used for future research In good general health without clinically significant medical history  FOR AND Less than 18 or greater than 75 years old A smoking history of 10 pack-years or more, a current smoker, or tobacco free for less than a year Positive HIV status. Subjects must have a negative FDA-approved HIV blood test Acute or chronic hepatitis based on viral hepatitis serologies Pregnancy or breastfeeding Any active medical problems especially bleeding disorders, significant bruising or bleeding difficulties with intramuscular (IM) injections or blood draws, use of anticoagulants, or pulmonary disorders including asthma History of allergic reaction to lidocaine, sedative medications like Valium Trademark or Versed Trademark, or narcotic medications like morphine or fentanyl Immunosuppressive medications, cytotoxic medications, inhaled corticosteroids, or long-acting beta-agonists within the past three months. (Note that use of corticosteroid nasal spray for allergic rhinitis, topical corticosteroids for an acute uncomplicated dermatitis, or short-acting beta-agonists in controlled asthmatics is not excluded) Use of platelet inhibitors including aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) within 7 days of procedure
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-12.0,  Ventilator Associated Pneumonia Children on mechanical ventilation for more than 72 hours and having simplified clinical pulmonary infection score more than 6 were included in study  Age less than 1 month
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cytomegalovirus Infections Orthotopic liver transplant recipient Donor CMV seropositive / Recipient CMV seronegative Enrolled within 10 days after liver transplant Able to swallow tablets  Multiple organ transplant HIV infection CMV disease Use of other anti-CMV therapy at time of enrollment
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-1.0,  Infection Precancerous/Nonmalignant Condition Adenosine deaminase-deficient severe combined immunodeficiency syndrome (ADA-SCIDs) CMV interstitial pneumonia based on the constellation of clinical and radiological findings Female Oxygen desaturation (pulse oximetry 85% on room air) Abnormal chest radiograph No CMV retinitis Prior ganciclovir and foscarnet sodium
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Leishmaniasis DoD healthcare beneficiary of any age and gender Clinicoepidemiologic or parasitologic diagnosis (microscopy, PCR or culture) of Leishmania infection Able to provide informed consent or assent (children) All participants (both male and female) must agree to take precautions not to become pregnant or father a child for at least 2 months after receiving SSG  Pregnancy. Females of childbearing potential must have negative urine human chorionic gonadotropin hormone (HCG) within 96 hours start of infusion period History of hypersensitivity to pentavalent antimonials Any of the following on screening examination QTc interval greater or equal to 0.5 sec Severe cardiac disease (disabling valvular heart disease, myopathy, or arrhythmias) History of recurrent pancreatitis Liver failure or active hepatitis with transaminases > 3x upper limit of normal Renal failure or creatinine > 2.5 mg/dL Thrombocytopenia (platelets <100,000/mm3) White blood cell count < 2000 / mm3
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cytomegalovirus Infection Age more than 18-year-old Informed consent  minors pregnant or lactating women adults under guardianship immunosuppression at the entrance to resuscitation AIDS
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease Men or women 40 years or above FEV1 between 40 and 80% of predicted normal value post-bronchodilator Clinical diagnosis of COPD  Other clinically relevant disease or disorders Exacerbation of COPD within 30 days
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cytomegalovirus Infection Male or female patients who fulfill the following are eligible for inclusion CMV D+/R liver, kidney, heart, pancreas, lungor combined transplant recipients All eligible patients must be scheduled to receive 3 months of either valganciclovir, oral ganciclovir, or intravenous ganciclovir prophylaxis Able to give written informed consent Are willing and able to comply with the protocol Age >=18 years  Patient unwilling or unable to give informed consent
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Asthma years of age or younger Scheduled for bronchoscopy at National Jewish Health for persistent asthma, persistent, poorly controlled wheezing, chronic cough, GERD, atelectasis, bronchopulmonary dysplasia, infection Consent and assent from parent and patient [if appropriate]  Unwillingness to consent/assent to retrieval of BAL fluid for research analysis
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.014,  Cytomegalovirus Disease All LBWIs whose weight is ≤ 1500 grams at birth LBWI is within first five days of life  LBWI not expected to live past first seven days of life LBWI has a severe congenital abnormality LBWI has received a RBC or platelet transfusion at another institution prior to transfer LBWI has received an in-utero transfusion LBWI is clinically suspected of having toxoplasmosis, rubella, herpes infection(s) at birth Refusal by the mother to grant consent for herself and/or refusal to grant consent for her LBWI If the mother of the child has previously participated in this study
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-12.0,  Post Bronchoscopy Fever under twelve years of age all patients undergoing bronchoscopy and bronchoalveolar lavage  children with immune deficiency allergy to previous exacerbation of asthma due to fever on the day of the examination current antibiotic treatment
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Chronic Beryllium Disease Diagnosis of chronic beryllium disease based on the below History of beryllium exposure, and Positive blood and/or bronchoalveolar lavage Beryllium Lymphocyte Proliferation Tests (BeLPT), and Biopsy-proven pathologic changes consistent with CBD-non-caseating granulomas and/or mononuclear cell interstitial infiltrates, and Positive bronchoalveolar lavage (BAL) BeLPT and > 15% lymphocytes in BAL fluid  History of Hepatic disease History of Renal disease Hypersensitivity to Pentasa (5-ASA) or salicylates Pregnancy Presence of another disease that may be expected to significantly affect patient mortality (e.g., HIV), severe cor pulmonale) The use of blood thinners Current use of tobacco (smoking or otherwise) in the past 6 months Patient inability to participate in the study, such as inability to undergo venipuncture and BAL procedures (if undergoing bronchoscopy) that form part of the inclusion/ or part of the outcome measure If undergoing bronchoscopy
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Invasive Aspergillosis BAL in hematological neutropenic patients at high risk of IA, admitted to our hospital, in which we usually perform a BAL for microbiological study when they present persistent fever and an opportunist infection suspicion BAL in patients without hematological illness and without IA suspicion, in which we perform an BAL because of another reason  Patients without fulfilling criteria Patients with some contraindication to perform a bronchoscopy
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Cytomegalovirus Infection Age 16 years or older cytomegalovirus seropositive allogeneic T cell depleted (alemtuzumab-containing conditioning regimen) hematopoietic stem cell transplant recipient with cytomegalovirus (CMV) seropositive unrelated donor Patient Informed consent Prepared to undergo additional study procedures as per study schedule Patient has undergone counselling about risk Donor engraftment (neutrophils > 0.5x109/l)(to be assessed prior to cytomegalovirus (CMV)-specific T cell infusion) Single positive cytomegalovirus PCR result (And to be assessed prior to cytomegalovirus (CMV)-specific T cell infusion) The donor will be selected from the Anthony Nolan Trust registry or other donor registries that have approved the protocol and consent procedure Donor must have met requirements of EU Tissue and Cells Directive(2004/23/EC) as amended and the UK statutory instruments pursuant therein Healthy, Cytomegalovirus (CMV)seropositive donor  Pregnant or lactating women Co-existing medical problems that would place the patient at significant risk of death due to Graft versus Host Disease (GVHD) or its sequelae Human immunodeficiency virus infection Active acute Graft versus Host Disease (GVHD) > Grade I (to be assessed prior to CMV-specific T cell infusion ) Concurrent use of systemic corticosteroids(to be assessed prior to cytomegalovirus (CMV)-specific T cell infusion ) Organ dysfunction (to be assessed prior to cytomegalovirus-specific T cell infusion ) as measured by creatinine > 200 uM/l bilirubin > 50 uM/l alanine transferase > 3x upper limit of normal Donor pregnant or lactating
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infections, Cytomegalovirus Subjects who the investigator believes that they can and will comply with the requirements of the protocol  A pregnant female, 18 years of age or older at the time of study enrolment Women with confirmed primary CMV infection Written informed consent obtained from the subject  Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to study entry Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational pharmaceutical product Previous vaccination against CMV infection Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history or physical examination Major congenital defects, serious chronic illness or organ transplantation Administration of immunoglobulins and/or any blood products within the three months preceding study enrolment or during the pregnancy Documented Human immunodeficiency virus (HIV)-positive subject Gestational age of more than 34 weeks, as determined by foetal ultrasound
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Mycoplasma Pneumonia Confirmed community acquired pneumonia 60ys≥age≥18 ys Respiratory symptom (cough accompanied by little or no sputum) New infiltration showed by chest radiology(x-ray or CT) Lung signs was not obvious White blood cell<10,000/mm3 Without underlying diseases or mild  Age<18ys or >60ys Pregnancy or breast-feeding Over one week after the onset of symptoms HIV infection Recent 90-day hospitalized history(length of stay greater than 2 days) Live in nursing homes or rehabilitation hospitals Taken macrolides or quinolones medicines before enrollment
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.5-6.0,  Infections, Respiratory Tract Subjects who the investigator believes that parent(s)/ legally acceptable representative can and will comply with the requirements of the protocol A male or female child between, and including, six to 72 months of age at the time of enrolment Written informed consent obtained from the parent(s)/ legally acceptable representative of the subject No antibiotic therapy within four weeks prior to the visit No cystic fibrosis or known major immunodeficiency such as agammaglobulinaemia, T cell deficiency or Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome No documented evidence or suspicion of gastroesophageal reflux disease No evidence of an upper viral respiratory infection four weeks prior to the visit In addition, all subjects regarded as 'cases' must satisfy all the following at study entry Persistent cough greater than eight weeks No response to five-day prednisolone treatment  Concurrently participating in another study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product Use of any investigational or non-registered product within 30 days prior to study procedures, or planned use during the study period Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination Child in care
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Drug Safety Patient age ≥ 18-year who received ventilator and agreed to participate by signing informed consent form  Immunocompromised host (e.g. HIV infection, On immunosupressive agents, ANC ≤ 500 cell/ml), Pregnancy, History of congenital heart disease, rheumatic fever, previously infective endocarditis, prosthetic valve, Contraindication for enteral feeding, History of milk or milk-product allergy
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Congenital Cytomegalovirus Infection Maternal Cytomegalovirus Infection Diagnosis of primary maternal CMV infection on the basis of one of the following A positive CMV Immunoglobulin M (IgM) antibody and low-avidity maternal CMV Immunoglobulin G (IgG) antibody screen Evidence of maternal seroconversion with development of CMV IgG antibody following a prior negative CMV screen Gestational age at randomization no later than 23 weeks 6 days based on clinical information and evaluation of the earliest ultrasound; or no later than 27 weeks 6 days for women with a positive IgM, negative IgG initially screened before 23 weeks who are rescreened after 2-4 weeks and have evidence of IgG seroconversion Singleton pregnancy. A twin pregnancy reduced to singleton (either spontaneously or therapeutically) before 14 weeks by project gestational age is acceptable  Maternal CMV infection pre-dating pregnancy as defined by a high IgG avidity index or a positive IgG in the presence of a negative IgM Known hypersensitivity to plasma or plasma derived products Planned termination of pregnancy Known major fetal anomalies or demise Maternal Immunoglobulin A (IgA) deficiency Planned use of immune globulin, ganciclovir, or valganciclovir Maternal renal disease (most recent pre-randomization serum creatinine ≥ 1.4 mg/dL; all women must have serum creatinine measured during the pregnancy and prior to randomization) Maternal immune impairment (e.g., HIV infection, organ transplant on anti-rejection medications) Findings on pre-randomization ultrasound suggestive of established fetal CMV infection (cerebral ventriculomegaly, microcephaly, cerebral or intra-abdominal calcifications, abnormalities of amniotic fluid volume, echogenic bowel or ascites). Abnormally low amniotic fluid volume is defined as no fluid prior to 14 weeks or maximum vertical pocket < 2 cm on or after 14 weeks gestation. Abnormally high amniotic fluid volume is defined as > 10 cm Positive fetal CMV findings from culture (amniotic fluid) or PCR